Concurrent Ocular Myopathy and Myasthenia Gravis After Zimberelimab Therapy in a Patient With Non-Small-Cell Lung Cancer

참고문헌 (9)

1. Vansteenkiste J, "Current status of immune checkpoint inhibition in early-stage NSCLC", Ann Oncol, 30, pp.1244~1253 (2019)
2. Psimaras D, "Immune checkpoint inhibitors-induced neuromuscular toxicity:from pathogenesis to treatment", J Peripher Nerv Syst, 24(Suppl 2), pp.S74~S85 (2019)
3. Amano Y, "Normal contrast enhancement of extraocular muscles : fat-suppressed MR findings", AJNR Am J Neuroradiol, 18, pp.161~164 (1997)
4. 허소영, "Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer", Journal of Clinical Neurology, 14(1), pp.115~117 (2018), 대한신경과학회[DOI]
5. Hibino M, "Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer", Respirol Case Rep, 6, pp.e00355~ (2018)
6. Garibaldi M, "Immune checkpoint inhibitors(ICIs)-related ocular myositis", Neuromuscul Disord, 30, pp.420~423 (2020)
7. Tian CY, "Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis : a case report", J Med Case Rep, 15, pp.244~ (2021)
8. Monstad SE, "CRMP5antibodies in patients with small-cell lung cancer or thymoma", Cancer Immunol Immunother, 57, pp.227~232 (2008)
9. 박영준, "Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance", Experimental and Molecular Medicine, 50, pp.1~13 (2018), 생화학분자생물학회

관련 논문AI추천